Claim 30% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
The latest update is out from Silexion Therapeutics ( (SLXN) ).
On February 3, 2026, Silexion Therapeutics used a new corporate presentation in a non-deal investor roadshow to highlight the progress and positioning of its RNAi oncology pipeline, led by SIL204, a first-in-class, isoform-selective pan-KRAS silencer formulated with targeted delivery. The company detailed how its dual-administration strategy for SIL204—combining intratumoral endoscopic delivery to penetrate the dense extracellular matrix of primary pancreatic tumors with systemic subcutaneous dosing to reach metastatic lesions—aims to improve outcomes in locally advanced and metastatic pancreatic cancer, as well as other KRAS-driven malignancies. Silexion underscored the magnitude of unmet need in pancreatic cancer, particularly in locally advanced disease where survival is poor and existing small-molecule RAS inhibitors leave significant efficacy and tolerability gaps, and presented Phase 2 data from its first-generation siRNA product Loder showing higher RECIST response rates, increased rates of tumors becoming resectable, and a median overall-survival gain of about 9.3 months versus standard-of-care chemotherapy alone in KRAS G12D/G12V locally advanced pancreatic cancer. The company framed SIL204 as a more advanced successor that leverages LDL receptor-mediated uptake, enriched in pancreatic and metastatic cancer cells, to preferentially deliver siRNA to tumors and potentially establish one of the most advanced RNAi-based oncology products in a highly competitive, high-mortality cancer market.
The most recent analyst rating on (SLXN) stock is a Hold with a $2.00 price target. To see the full list of analyst forecasts on Silexion Therapeutics stock, see the SLXN Stock Forecast page.
Spark’s Take on SLXN Stock
According to Spark, TipRanks’ AI Analyst, SLXN is a Neutral.
The score is held down primarily by weak financial performance (no revenue, ongoing losses, and accelerating cash burn) and a bearish technical setup (below key moving averages with negative MACD). Positive corporate developments around regulatory progress and trial preparations provide an offset, but valuation metrics are not informative/supportive due to negative earnings and no stated dividend.
To see Spark’s full report on SLXN stock, click here.
More about Silexion Therapeutics
Silexion Therapeutics Corp. is a development-stage oncology biotech focused on RNA interference (RNAi) therapeutics that silence oncogenes at the gene-expression level, with a particular emphasis on cancers driven by KRAS mutations. Its lead technology platform centers on siRNA-based agents designed to target both active and inactive KRAS, addressing historically “undruggable” tumors such as pancreatic ductal adenocarcinoma, colorectal cancer and non-squamous non-small-cell lung cancer, where KRAS mutations are prevalent and current treatment options and survival outcomes remain poor.
Average Trading Volume: 57,574
Technical Sentiment Signal: Strong Sell
Current Market Cap: $5.72M
For detailed information about SLXN stock, go to TipRanks’ Stock Analysis page.